414 related articles for article (PubMed ID: 32507098)
1. A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Malkan UY; Albayrak M; Yildiz A; Maral S; Afacan Ozturk HB; Comert P
J Oncol Pharm Pract; 2021 Jan; 27(1):250-252. PubMed ID: 32507098
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
Yu M; Zhang Q; Xu S; Yin T; Li F
Anticancer Drugs; 2022 Jan; 33(1):e769-e775. PubMed ID: 34387604
[TBL] [Abstract][Full Text] [Related]
3. The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.
Wang J; Wang D; Zhang Q; Duan L; Tian T; Zhang X; Li J; Qiu H
J Cancer Res Clin Oncol; 2016 Apr; 142(4):859-71. PubMed ID: 26666755
[TBL] [Abstract][Full Text] [Related]
4. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
5. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
6. Case Report Diffuse large B-cell lymphoma in the primary bone marrow.
Hu Y; Chen SL; Huang ZX; Gao W; An N
Genet Mol Res; 2015 Jun; 14(2):6247-50. PubMed ID: 26125825
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Hanna F; Prakash A; Allan E; Khalafallah AA
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29549134
[TBL] [Abstract][Full Text] [Related]
8. Intravascular large B-cell lymphoma associated with silicone breast implant, HLA-DRB1*11:01, and HLA-DQB1*03:01 manifesting as macrophage activation syndrome and with severe neurological symptoms: a case report.
Moling O; Piccin A; Tauber M; Marinello P; Canova M; Casini M; Negri G; Raffeiner B; Binazzi R; Gandini L; Vecchiato C; Rimenti G; Billio A
J Med Case Rep; 2016 Sep; 10(1):254. PubMed ID: 27634631
[TBL] [Abstract][Full Text] [Related]
9. Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome.
Nakayama S; Morita Y; Espinoza JL; Rai S; Taniguchi Y; Taniguchi T; Miyake Y; Tanaka H; Ashida T; Matsumura I
Ann Hematol; 2020 Feb; 99(2):381-383. PubMed ID: 31768673
[No Abstract] [Full Text] [Related]
10. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.
Hu S; Bansal P; Lynch D; Rojas Hernandez CM; Dayao Z
J Med Case Rep; 2016 Dec; 10(1):365. PubMed ID: 27998299
[TBL] [Abstract][Full Text] [Related]
11. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
[TBL] [Abstract][Full Text] [Related]
12. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
14. Hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus-positive diffuse large B-cell lymphoma, NOS of bone marrow-liver-spleen type: an autopsy case report.
Iizuka H; Mori Y; Iwao N; Koike M; Noguchi M
J Clin Exp Hematop; 2021 Jun; 61(2):102-108. PubMed ID: 33994430
[TBL] [Abstract][Full Text] [Related]
15. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
[TBL] [Abstract][Full Text] [Related]
16. A rare case of primary high-grade large B-cell lymphoma of the sciatic nerve.
Advani P; Paulus A; Murray P; Jiang L; Goff R; Pooley R; Jain M; Garner H; Foran J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e117-20. PubMed ID: 25617034
[No Abstract] [Full Text] [Related]
17. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: a case report.
Wu R; Deng X; Hao S; Ma L
J Int Med Res; 2020 Feb; 48(2):300060519882233. PubMed ID: 31642356
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
[TBL] [Abstract][Full Text] [Related]
20. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S
Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
